Metabolic barriers to cancer immunotherapy

被引:336
|
作者
DePeaux, Kristin [1 ,2 ]
Delgoffe, Greg M. [1 ,2 ]
机构
[1] UPMC Hillman Canc Ctr, Tumor Microenvironm Ctr, Pittsburgh, PA 15232 USA
[2] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA
关键词
CD8(+) T-CELLS; MEMORY STEM-CELLS; B-CELL; AEROBIC GLYCOLYSIS; CRITICAL REGULATOR; IMMUNE RESISTANCE; RECEPTOR PD-1; ION CHANNELS; CHECKPOINT; CTLA-4;
D O I
10.1038/s41577-021-00541-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several non-redundant features of the tumour microenvironment facilitate immunosuppression and limit anticancer immune responses. These include physical barriers to immune infiltration, the recruitment of suppressive immune cells and the upregulation of ligands on tumour cells that bind to inhibitory receptors on immune cells. Recent insights into the importance of the metabolic restrictions imposed by the tumour microenvironment on antitumour T cells have begun to inform immunotherapeutic anticancer strategies. Therapeutics that target metabolic restrictions, such as low glucose levels, a low pH, hypoxia and the generation of suppressive metabolites, have shown promise as combination therapies for different types of cancer. In this Review, we discuss the metabolic aspects of the antitumour T cell response in the context of immune checkpoint blockade, adoptive cell therapy and treatment with oncolytic viruses, and discuss emerging combination strategies.
引用
收藏
页码:785 / 797
页数:13
相关论文
共 50 条
  • [31] Natural Killer Cells in Cancer and Cancer Immunotherapy
    Raskov, Hans
    Orhan, Adile
    Salanti, Ali
    Gaggar, Shruti
    Gogenur, Ismail
    CANCER LETTERS, 2021, 520 : 233 - 242
  • [32] Perspectives for immunotherapy in endocrine cancer
    Latteyer, S.
    Tiedje, V.
    Schilling, B.
    Fuehrer, D.
    ENDOCRINE-RELATED CANCER, 2016, 23 (10) : R469 - R484
  • [33] A review of cancer immunotherapy toxicity
    Kennedy, Lucy Boyce
    Salama, April K. S.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (02) : 86 - 104
  • [34] Autoimmune complications of cancer immunotherapy
    Dhodapkar, Kavita M.
    CURRENT OPINION IN IMMUNOLOGY, 2019, 61 : 54 - 59
  • [35] Oncolytic Viruses in Cancer Immunotherapy
    Li, Xiao
    Cheng, Zhongping
    ADVANCED THERAPEUTICS, 2024, 7 (07)
  • [36] Immunotherapy in rare ovarian cancer
    Laga, Tina
    Vergote, Ignace
    Van Nieuwenhuysen, Els
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (05) : 447 - 456
  • [37] Neurological complications of cancer immunotherapy
    Roth, Patrick
    Winklhofer, Sebastian
    Muller, Antonia M. S.
    Dummer, Reinhard
    Mair, Maximilian J.
    Gramatzki, Dorothee
    Le Rhun, Emilie
    Manz, Markus G.
    Weller, Michael
    Preusser, Matthias
    CANCER TREATMENT REVIEWS, 2021, 97
  • [38] Advancing to the era of cancer immunotherapy
    Wang, Yun
    Wang, Min
    Wu, Hao-Xiang
    Xu, Rui-Hua
    CANCER COMMUNICATIONS, 2021, 41 (09) : 803 - 829
  • [39] Possible Biomarkers for Cancer Immunotherapy
    Otoshi, Takehiro
    Nagano, Tatsuya
    Tachihara, Motoko
    Nishimura, Yoshihiro
    CANCERS, 2019, 11 (07)
  • [40] The Discovery of Biomarkers in Cancer Immunotherapy
    George, Anil P.
    Kuzel, Timothy M.
    Zhang, Yi
    Zhang, Bin
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2019, 17 : 484 - 497